Takeda Biopharmaceuticals India Private Limited demonstrated its innovative digital healthcare solutions at the G20 Health Working Group meeting held in Goa, India. The event aimed to create a digital health ecosystem, discuss innovations in healthcare, explore how technology can aid continuing Takeda Biopharmaceuticals India Pvt Ltd, a global biopharmaceutical company, participated in the G20 Health Working Group meeting in Goa, India, from April 17th to April 19th. The G20 Health Working Group is a forum that brings together health experts and policymakers from the world’s 20 largest economies to discuss key health issues and develop policy recommendations. This year’s theme was “Citizen-Centric Health Delivery Ecosystems for Universal Health Coverage leveraging Digital Health and Innovations.”
At the G20 meeting, Takeda showcased its cutting-edge digital innovations in healthcare. Three solutions were presented, namely MyPKFit, Synapse, and Athena. MyPKFit is an FDA-approved application that enables personalized and interactive prophylaxis treatment options. It allows healthcare professionals and patients to monitor factor VIII levels on smartphones in real-time, thereby enabling them to make informed decisions about their activity levels and improve their quality of life. Alerts are sent to patients on prophylaxis when their estimated factor VIII levels are low, and it reminds them when their infusions are due, thereby providing excellent prophylactic coverage.
Synapse is another valuable platform designed to enhance awareness and knowledge sharing among healthcare professionals in line with Takeda’s core philosophy of “better health, brighter future.” The platform’s primary objective is to improve awareness and enhance standards of care, thereby optimizing patient benefits. It also fosters academic partnerships with scientific societies to help build quality healthcare professional education and awareness. In essence, Synapse is a comprehensive and innovative platform that seeks to empower healthcare professionals with the knowledge and tools necessary to make a positive impact on patients’ lives.
Finally, the Athena App MVP is a digital health solution that enables remote patient data capture and improved patient engagement for Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer (NSCLC) patients, their caregivers, and healthcare professionals. The Athena App MVP leverages a smartphone app integrated with consumer wearables and empowers patients to easily track, understand, and communicate simple, robust measures of quality of life. It also provides a way for healthcare professionals to engage holistically with patient quality of life, including personal goals, activity, sleep, mental health, and cognition. Furthermore, the validated data collected from the MVP can be used by Takeda to demonstrate real-world outcomes and develop novel solutions.
In conclusion, Takeda’s digital solutions aim to improve patient outcomes and advance healthcare access. The G20 meeting provided a platform for Takeda to showcase its capabilities and explore potential collaborations with G20 member countries. By leveraging digital solutions, Takeda can transform healthcare and create a brighter future for patients and the healthcare ecosystem.
